News Today:
Skinvisible Pharmaceuticals, Inc. Announces New Agreement To Sell its Proprietary Polymer
Grants License to Essentially Yours Industries of Canada to Manufacture And Sell a Private Line of Skin Products Using Skinvisible's Patent-Pending Topical Delivery Technology
LAS VEGAS, Feb. 17 /PRNewswire/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI) announced today that its wholly
owned subsidiary Skinvisible Pharmaceuticals, Inc. has signed two new agreements with British Columbia based network marketer, Essentially Yours Industries Corp. ("EYI"). Under the agreements, EYI will purchase Skinvisible's proprietary polymer base composition and has acquired a license to manufacture and sell a private line of antimicrobial skin protector products utilizing Skinvisible's patent-pending topical delivery technology.
The new agreements replace those signed last year with Essentially Yours Industries Corp. and EYI International Limited for product distribution.
EYI has experienced strong positive customer response to the Skinvisible line of products. The new agreement allows EYI to take advantage of this demand by commercializing its own label. The terms of the Skinvisible license allow EYI to use the unique delivery technology in developing other products beyond the antimicrobial skin protectant.
This move is consistent with Skinvisible's long term strategy of focusing on its core topical delivery system technology, a proprietary polymer composition that forms an electrochemical bond with skin surface layers. The polymer emulsions demonstrate persistence on the skin, lasting for up to four hours.
Headquartered in Las Vegas, Nevada, Skinvisible Pharmaceuticals, Inc. develops and markets an innovative and unique topical delivery technology that has broad applications in the medical, healthcare, food handling & service, industrial, salon, cosmetic and personal care areas. Skinvisible also develops and markets a family of skin protector products that utilize this technology
for direct or private label commercialization.
This press release contains "forward looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc.
reports that will be on file with the US Securities and Exchange Commission (including but not limited to the report on Form 10-QSB for the quarter ended September 30, 1999). |
